Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication CELEBREX is indicated CELEBREX is a nonsteroidal anti-inflammatory drug indicated for: • Osteoarthritis (OA) ( 1.1 ) • Rheumatoid Arthritis (RA) ( 1.2 ) • Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older ( 1.3 ) • Ankylosing Spondylitis (AS) ( 1.4 ) • Acute Pain (AP) ( 1.5 ) • Primary Dysmenorrhea (PD) ( 1.6 ) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA [see Clinical… FDA label
Also known as Celebrex capsule
Celebrex · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Celebrex | DRUG | - |
Inclusion Criteria: * diagnosis of OA of the knee according to the ACR Classification Criteria for osteoarthritis; * patients in flare Exclusion Criteria: * any concomitant inflammatory rheumatic condition which may interfere with the assessment of OA * clinical or radiological evidence of chondr...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Celebrex is a small molecule medicine developed by Pfizer, Inc. (ticker PFE) for musculoskeletal conditions. It has been studied in knee osteoarthritis, a degenerative joint condition. The clinical program includes a completed Phase 3 trial, NCT00137410, titled Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee, which enrolled 200 participants in Italy.
Celebrex has been evaluated for the treatment of osteoarthritis of the knee. A completed Phase 3 study, NCT00137410, examined short versus long therapy with Celebrex in adults aged 50 years and older with knee osteoarthritis. The trial enrolled 200 participants in Italy and was randomized and double blind.
Celebrex is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company associated with the clinical development program for Celebrex in knee osteoarthritis.
Celebrex has been studied in Phase 3 clinical development for knee osteoarthritis. The program includes one completed Phase 3 trial, NCT00137410, with 200 participants. No active trials are currently listed for this asset.
Celebrex has been studied in the Phase 3 trial NCT00137410, titled Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee. The trial was completed, enrolled 200 participants, was randomized and double blind, and was conducted in Italy in adults aged 50 years and older.
Yes, Celebrex capsule is another name for Celebrex. Both refer to the same medicine developed by Pfizer, Inc. (ticker PFE) that has been studied in Phase 3 for knee osteoarthritis.